Idera Pharmaceuticals, Inc. Presents Preclinical Data In Lupus Disease Models On Use Of Novel Class Of Antagonists For Toll-Like Receptors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals Inc. (AMEX: IDP), today announced the presentation of preclinical data using antagonists of Toll-like receptor (TLR) 7 and 9 in mouse models of lupus disease. The presentation entitled “Novel Class of DNA-Based Compounds Act as Antagonists for TLR7 and 9: In Vitro and In Vivo Studies in MRL-lpr and NZBW/F1 Mouse Models” (Abstract #473) was made at the Keystone Symposia’s Biology of B Cells in Health and Disease being held in Banff, Alberta, Canada, February 6-12, 2006.